EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 383 filers reported holding EXELIXIS INC in Q1 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $12,223,000 | +15.9% | 621,400 | +4.4% | 0.58% | +51.0% |
| Q3 2018 | $10,543,000 | -17.7% | 595,000 | 0.0% | 0.38% | -22.5% |
| Q2 2018 | $12,804,000 | +230.3% | 595,000 | +240.0% | 0.49% | +198.8% |
| Q1 2018 | $3,876,000 | -27.1% | 175,000 | 0.0% | 0.16% | -31.5% |
| Q4 2017 | $5,320,000 | +25.5% | 175,000 | 0.0% | 0.24% | +23.0% |
| Q3 2017 | $4,240,000 | -1.6% | 175,000 | 0.0% | 0.20% | -10.1% |
| Q2 2017 | $4,310,000 | +13.7% | 175,000 | 0.0% | 0.22% | -0.5% |
| Q1 2017 | $3,792,000 | +45.3% | 175,000 | 0.0% | 0.22% | +25.1% |
| Q4 2016 | $2,609,000 | +63.2% | 175,000 | +40.0% | 0.18% | +75.0% |
| Q3 2016 | $1,599,000 | +135.8% | 125,000 | -37.5% | 0.10% | -18.0% |
| Q2 2014 | $678,000 | -23.0% | 200,000 | -19.7% | 0.12% | -39.9% |
| Q1 2014 | $881,000 | -4.2% | 249,000 | +66.0% | 0.20% | -38.3% |
| Q4 2013 | $920,000 | – | 150,000 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |